Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's diseaseLeveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果